Real-world GPP data show low uptake of targeted IL-36 inhibitors and persistent reliance on corticosteroids and non-GPP ...

Dr Ablon discusses important key points providers should keep in mind during their evaluations of patients seeking aesthetic ...

Risk for ischemic stroke, myocardial infarction were increased with prolonged use with doses >1 mg/day for more than one year ...

Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...

The novel oral helicase-primase inhibitor offers a non-intravenous option for immunocompromised adults with mucocutaneous HSV refractory to standard antivirals.

BRAVE-AA-PEDS data presented at FC26 show baricitinib maintained significant hair regrowth through 76 weeks in adolescents with severe alopecia areata.

"Because evidence on GLP-1 exposure during breastfeeding remains limited, rising postpartum initiation warrants further study." HealthDay News — Postpartum initiation of glucagon-like peptide-1 ...

Statin treatment also associated with lower risks for treatment escalation, including surgery, topical ocular hypotensive prescription.

Adjuvant atezolizumab combined with mFOLFOX6 halved the risk of disease recurrence or death in patients with resected stage III mismatch repair–deficient colon cancer in the phase 3 ATOMIC trial.

Many approved prescriptions are never filled, with fill rates dropping sharply when out-of-pocket costs exceed $175.

Second study shows that individuals exposed to GLP-1 RAs have significantly higher prevalence rates of hair and scalp involvement.

Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...